Greenwich LifeSciences (GLSI) EBITDA Margin: History & Chart

Greenwich LifeSciences, Inc.(GLSI)

Biotechnology · Stafford, TX

$16.91-0.07 (-0.41%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.

Stafford, TX

13 employees

greenwichlifesciences.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Snehal S. Patel

View full financials

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
Greenwich LifeSciences, Inc. (GLSI)	$248.21M	N/A	N/A	N/A	N/A
InflaRx N.V. (IFRX)vs ›	$247.45M	-163095.33%	-97357.05%	-88166.59%	-88166.59%
Invivyd, Inc. (IVVD)vs ›	$247.23M	-100.05%	-392.29%	-392.29%	-392.29%
Galectin Therapeutics Inc. (GALT)vs ›	$245.65M	N/A	N/A	N/A	N/A
CAMP4 Therapeutics Corporation (CAMP)vs ›	$251.64M	-1441.45%	-4661.83%	-5918.79%	-3944.51%
Akebia Therapeutics, Inc. (AKBA)vs ›	$244.25M	10.49%	1.20%	-4.19%	-40.04%
High Tide Inc. (HITI)vs ›	$239.89M	1.66%	3.74%	-1.53%	0.81%
BioAge Labs Inc. (BIOA)vs ›	$239.45M	-1029.09%	-1029.09%	-1029.09%	-1029.09%
Eupraxia Pharmaceuticals Inc. (EPRX)vs ›	$259.30M	N/A	N/A	N/A	N/A
Biodesix, Inc. (BDSX)vs ›	$236.56M	-25.05%	-32.88%	-63.97%	-61.52%

NAME

MARKET CAP

EBITDA MARGIN

TTM

Greenwich LifeSciences, Inc. (GLSI)

$248.21M

N/A

InflaRx N.V. (IFRX)vs ›

$247.45M

-163095.33%

-97357.05%

-88166.59%